HEPATAMINE 8% Drug Patent Profile
✉ Email this page to a colleague
When do Hepatamine 8% patents expire, and when can generic versions of Hepatamine 8% launch?
Hepatamine 8% is a drug marketed by B Braun and is included in one NDA.
The generic ingredient in HEPATAMINE 8% is amino acids. There are three hundred and fifty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the amino acids profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hepatamine 8%
A generic version of HEPATAMINE 8% was approved as amino acids by B BRAUN on April 13th, 2012.
Summary for HEPATAMINE 8%
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HEPATAMINE 8% at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HEPATAMINE 8%
US Patents and Regulatory Information for HEPATAMINE 8%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
B Braun | HEPATAMINE 8% | amino acids | INJECTABLE;INJECTION | 018676-001 | Aug 3, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HEPATAMINE 8%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
B Braun | HEPATAMINE 8% | amino acids | INJECTABLE;INJECTION | 018676-001 | Aug 3, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for HEPATAMINE 8%
See the table below for patents covering HEPATAMINE 8% around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 1050890 | FORMULE A BASE D'ACIDES AMINES POUR NOURRIR LES MALADES ATTEINTS DE MALADIES DU FOIE ET METHODE D'UTILISATION (AMINO ACID FORMULATIONS FOR PATIENTS WITH LIVER DISEASE AND METHOD OF USING SAME) | ⤷ Try a Trial |
Japan | S5627493 | ⤷ Try a Trial | |
Sweden | 425715 | FORFARANDE FOR FRAMSTELLNING AV ETT AMINOSYRAPREPARAT, AVSETT FOR ADMINISTRATION TILL HUMANPATIENTER MED LEVERSJUKDOM | ⤷ Try a Trial |
Belgium | 838231 | ⤷ Try a Trial | |
Japan | S51118839 | AMINO ACID PHARMACY FOR LIVERISH PATIENT DOSAGE | ⤷ Try a Trial |
United Kingdom | 1507951 | ⤷ Try a Trial | |
New Zealand | 179655 | A MIXTURE OF ESSENTIAL AND NON-ESSENTIAL AMINO ACIDS FOR HUMANS | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for HEPATAMINE 8%
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0812190 | SPC/GB05/042 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MESYLATE, ESYLATE OR SULFATE SALTS OF N-PROPARGYL-1(R)-AMINOINDAN (RASAGILINE); REGISTERED: UK EU/1/04/304/001 20050221; UK EU/1/04/304/002 20050221; UK EU/1/04/304/003 20050221; UK EU/1/04/304/004 20050221; UK EU/1/04/304/005 20050221; UK EU/1/04/304/006 20050221; UK EU/1/04/304/007 20050221 |
0252504 | SPC/GB96/060 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IBANDRONIC ACID ((1-HYDROXY-3-(METHYLPENTYLAMINO) - PROPYLIDINE)-DIPHOSPHONIC ACID); REGISTERED: UK EU/1/96/012/001 19960625 |
2404919 | 122016000035 | Germany | ⤷ Try a Trial | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, ODER EIN ESTER-PRODRUG DAVON.; REGISTRATION NO/DATE: EU/1/15/1059 20151119 |
1732548 | C300515 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: 4-AMINOPYRIDINE EN DERIVATEN DAARVAN; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720 |
2340828 | 2021C/502 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS HET SACUBITRIL VALSARTAN NATRIUMZOUTCOMPLEX, I.E. (((S)-N-VALERYL-N-((2'-(1H-TETRAZOL-5-YL)-BIFENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIFENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTAANZUURETHYLESTER))NA3 . X H2O, WAARBIJ X 0 TOT 3 IS; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 (C(2015) 8288) 20151123 |
1613288 | C 2011 005 | Romania | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMOD SI SARURILE SALE ACCEPTABILE FARMACEUTIC INSPECIAL SARE CLORHIDRAT 2-AMINO-2[2-(4-OCTILFENIL)ETIL]PROPAN-1,3 DIOL; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/677/001, RO EU/1/11/677/002, RO EU/1/11/677/003, RO EU/1/11/677/004; DATE OF NATIONAL AUTHORISATION: 20110317; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/677/001, EMEA EU/1/11/677/002, EMEA EU/1/11/677/003, EMEA EU/1/11/677/004; DATE OF FIRST AUTHORISATION IN EEA: 20110317 |
2395002 | 300812 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPAANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOEZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1059 20151124 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |